Highlights

• Sun Pharma’s Q3 FY26 revenue grew 11% year-on-year to ₹143,458 million.
• The US formulations segment contributed 28% of sales, rising 14.8% compared to last year.
• Regulatory approvals were received for semaglutide generics in weight management and type 2 diabetes in India.

Sun Pharmaceutical Industries reported total revenue of ₹143,458 million in Q3 FY26, marking an 11% increase over ₹128,822 million in Q3 FY25. The company achieved EBITDA of ₹42,949 million, a 12.6% rise, with a margin of 29.9%. Adjusted net profit stood at ₹28,349 million, reflecting a 12% increase from the prior year. Research and development spending for the quarter totaled ₹9,141 million, representing 6.4% of sales, reflecting continued focus on specialty therapies and regulated markets.

Geographic and Segment Mix
Revenue in Q3 FY26 was driven by a diversified global base. India Branded Generics contributed ₹45,630 million, accounting for 32% of sales and growing 10.6%. US Formulations represented ₹40,845 million, contributing 28% of total sales with a 14.8% increase year-on-year. Emerging Markets delivered ₹27,249 million, making up 19% of sales, with 9.3% growth.

The Rest of World (RoW) segment contributed ₹23,809 million, 17% of total revenue, up 11%, while API & Others represented 4% of sales. This diversified composition highlights balanced performance across mature and emerging markets.

Operational Adjustments
Q3 FY26 adjusted net profit included ₹1,679 million of specific items. This comprised additional provisions for GxMDL amounting to ₹1,140 million and costs related to the Wage Code totaling ₹3,755 million. Offsetting tax benefits were recorded for GxMDL (₹1,905 million) and the Wage Code (₹1,311 million). These adjustments ensure transparency in reporting while reflecting compliance with regulatory requirements.

Specialty Focus and DCGI Approvals
Sun Pharma received approval from DCGI to manufacture and market a generic semaglutide injection for chronic weight management, branded as Noveltreat. The product is available in five dose strengths (0.25–2.4 mg) administered through a prefilled pen. Earlier, in December 2025, approval was also granted for semaglutide in type 2 diabetes, branded Sematrinity. Both approvals followed Phase III clinical trials conducted in India, targeting obesity and cardiometabolic health challenges.

Share Performance
The stock of Sun Pharma closed at ₹1,763.3, up 1.82% from its previous close of ₹1,731.8. The intraday high reached ₹1,770.4 while the low touched ₹1,733.4, with an opening price of ₹1,742. Total trading volume was 1,200,996 shares, reflecting significant investor participation. The upward movement coincided with quarterly financial performance and regulatory approvals, positioning Sun Pharma among NIFTY 50 gainers.

Sun Pharma recorded 11% revenue growth in Q3 FY26, led by US formulations and India branded generics. Adjusted net profit increased 12% with 6.4% of sales invested in R&D. DCGI approvals for semaglutide in weight management and type 2 diabetes reinforce its specialty focus. The stock gained 1.82%, reflecting investor attention to both operational and regulatory developments.

FAQs

Q1: What contributed to Sun Pharma’s revenue growth in Q3 FY26?
Revenue growth was primarily driven by US formulations, India branded generics, and emerging markets.

Q2: Why are the DCGI approvals significant?
The approvals enable generic semaglutide access for chronic weight management and type 2 diabetes in India.

Q3: How did Sun Pharma’s stock perform recently on NSE?
The stock closed at ₹1,763.3, up 1.82% with strong intraday trading and active volumes.